Effect of vigorous-intensity physical activity on incident cognitive impairment in high-risk hypertension

Alzheimers Dement. 2024 Jul;20(7):4602-4612. doi: 10.1002/alz.13887. Epub 2024 Jun 6.

Abstract

Introduction: We investigated the effect vigorous physical activity (VPA) on the risk of incident mild cognitive impairment (MCI) and probable dementia among individuals with high-risk hypertension.

Methods: Baseline self-reported frequency of VPA was categorized into low VPA (<1 session/week), and high VPA (≥1 session/week). We used multivariate Cox regression analysis to examine the association of VPA categories with incident MCI and probable dementia events.

Results: Participants in the high VPA category, compared with low VPA, experienced lower events rates (per 1000 person-years) of MCI (13.9 vs 19.7), probable dementia (6.3 vs 9.0), and MCI/probable dementia (18.5 vs 25.8). In the multivariate Cox regression model, high VPA, compared with low VPA, was associated with lower risk of MCI, probable dementia, and MCI/probable dementia (HR [95% CI]: 0.81 [0.68-0.97], 0.80 [0.63-1.03], and 0.82 [0.70-0.96]), respectively.

Discussion: This study provides evidence that VPA may preserve cognitive function in high-risk patients with hypertension.

Highlights: Hypertension is associated with an increased risk of cognitive impairment Physical activity (PA) is associated with a lower risk of decline in cognition The effect of ≥1 sessions of vigorous-intensity PA (VPA) per week was assessed This analysis included SPRINT MIND trial participants with high-risk hypertension ≥1 VPA sessions/week was associated with lower risk of future cognitive impairment.

Trial registration: ClinicalTrials.gov NCT01206062.

Keywords: cognitive impairment; dementia; hypertension; mild cognitive impairment; physical activity.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Cognitive Dysfunction* / epidemiology
  • Dementia / epidemiology
  • Exercise*
  • Female
  • Humans
  • Hypertension* / epidemiology
  • Incidence
  • Male
  • Middle Aged
  • Risk Factors

Associated data

  • ClinicalTrials.gov/NCT01206062